Heart Attack Diagnostic Global Market Report 2024

The primary types of heart attack diagnostic tests include electrocardiogram (ECG/EKG), blood tests, X-ray, echocardiogram, coronary catheterization (angiogram), exercise stress test, and magnetic resonance imaging (MRI). These tests can be conducted through both invasive and non-invasive procedures. An electrocardiogram (ECG) is a rapid test that assesses the heart's electrical activity and rhythm by detecting signals produced during each heartbeat. It is valuable for diagnosing and monitoring heart-related conditions. These heart attack diagnostics are employed in various healthcare settings, including hospitals, ambulatory surgical centers, diagnostic centers, and other end-users.

This report provides heart attack diagnostics market statistics, including heart attack diagnostics industry global market size, regional shares, competitors with a heart attack diagnostics market share, detailed heart attack diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the heart attack diagnostics industry. This heart attack diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global heart attack diagnostic market has grown strongly in recent years. It will grow from $10.21 billion in 2023 to $11.07 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to the development of cardiac biomarkers, the introduction of ECG and imaging, the standardization of diagnostic protocols, awareness, and education initiatives, as well as improvements in troponin testing.

The global heart attack diagnostic market is expected to see strong growth in the next few years. It will grow to $15.26 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the forecast period can be attributed to factors such as patient empowerment and engagement, the use of data analytics and precision medicine, initiatives in preventive healthcare, ongoing development of healthcare infrastructure, and the adoption of personalized diagnostic approaches. Major trends expected in this period include the implementation of point-of-care testing, the use of high-sensitivity troponin tests, the advancement of non-invasive imaging techniques, the continued progress in personalized medicine, and the increasing use of remote monitoring devices in the healthcare industry.
The heart attack diagnostics market is experiencing substantial growth, driven by the escalating prevalence of cardiac disorders globally. Cardiac disorders, constituting a group of conditions affecting the heart and blood vessels, are exacerbated by lifestyle factors such as unhealthy eating, physical inactivity, tobacco use, and alcohol abuse. Heart attack diagnostics play a pivotal role in analyzing the causes and severity of heart attacks, strokes, and heart failure. According to a 2021 World Health Organization (WHO) study, cardiovascular diseases (CVDs) accounted for 17.9 million deaths worldwide, comprising 32% of total deaths, with 85% attributed to heart attacks and strokes. This alarming rise in cardiovascular diseases, responsible for one-third of global deaths, underscores the continuous growth trajectory of the heart attack diagnostics market.

The heart attack diagnostics market is poised for growth, buoyed by the increasing expenditure in the healthcare sector. Healthcare expenditure, measured as the total cost of healthcare (including public and private spending) as a percentage of GDP, creates an environment conducive to innovation, research, and infrastructure development. This heightened investment contributes to the advancement and expansion of the heart attack diagnostics market. A notable example is the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services, projecting an annual growth rate of 5.1%, reaching nearly $6.8 trillion by 2030. The anticipated growth in Medicare and Medicaid spending further underscores the significant impact of increased healthcare expenditure on the heart attack diagnostics market.

An influential trend in the heart attack diagnostics market is the development of novel diagnostic techniques, particularly leveraging artificial intelligence (AI). Major players in the market are investing in cutting-edge technologies to enhance heart disease diagnosis. AI, an emulation of human intellect, is being deployed to improve diagnostic radiography, expedite heart problem diagnoses, and enhance stroke treatment. A notable instance is the development of an AI-based method by physician-scientists at Cedars-Sinai's Smidt Heart Institute. This AI program excels in identifying hard-to-diagnose cardiac conditions, effectively predicting accurate diagnoses by recognizing patterns invisible to the human eye. This trend signifies a paradigm shift in heart attack diagnostics, ushering in advanced capabilities for accurate and timely diagnoses.

Major companies in the heart attack diagnostics market are at the forefront of innovation, introducing groundbreaking products such as coronary heart disease detection tests. These tests are designed to identify the presence of coronary heart disease, characterized by the narrowing or blockage of coronary arteries. A notable product in this category is the PrecisionCHD test launched by Cardio Diagnostics Holdings Inc. This blood-based detection method for Coronary Heart Disease (CHD) uniquely integrates epigenetic and genetic biomarkers with Artificial Intelligence (AI). Notably, the PrecisionCHD test provides a rapid and efficient alternative to traditional CHD detection tools, offering convenience with a straightforward blood sample and swift results within 10 business days. This innovation reflects the commitment of major companies to meet evolving customer needs, drive sales, and elevate revenue in the heart attack diagnostics market.

In November 2021, Royal Philips, a leading Netherlands-based multinational conglomerate corporation specializing in health technology, successfully acquired Cardiologs for an undisclosed amount. This strategic acquisition was aimed at enhancing Philips' capabilities in cardiac monitoring and diagnostics. Cardiologs, a France-based medical technology company, is recognized for its innovative use of artificial intelligence (AI) and cloud technology in transforming cardiac diagnostics. The integration of Cardiologs' advanced software technology, electrocardiogram (ECG) analysis, and reporting services into Philips' offerings further solidifies its position in providing cutting-edge solutions in the healthcare sector.

Major companies operating in the heart attack diagnostic market report are Abbott Laboratories, F. Hoffmann-La Roche AG, General Electric Co., Hitachi Ltd., Koninklijke Philips NV, Midmark Corp., Siemens AG, Toshiba Corp., Welch Allyn Inc., Astrazenca PLC., HILL ROM HOLDINGS Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., Fujifilm Holdings, ACS Diagnostics Inc., Beckman Coulter Inc., Schiller AG, GE Healthcare, HeartFlow, Medtronic PLC, Cardio Diagnostics Holdings Inc., Beckman Coulter Inc., Becton Dickinson and Company, Danaher Corporation, Edwards Lifesciences Corporation, Illumina Inc., Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Quest Diagnostics, Roche Diagnostics, and Thermo Fisher Scientific Inc.

North America was the largest region in the heart attack diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heart attack diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the heart attack diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The heart attack diagnostics market includes revenues earned by entities through tests such as stress tests, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), and angiogram. The market value includes the value of related goods sold by the service provider or included within the service offering. The heart attack diagnostics market also includes sales of wearable ECG devices, cardiac pacemakers, stents, and ventricular assist devices (VADs) which are used in heart attack diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.